依达拉奉右莰醇对急性脑梗死患者神经功能恢复的效果OA
Effect of Edaravone Dexborneol on Neurological Function Recovery in Patients with Acute Cerebral Infarction
目的 评价依达拉奉右莰醇对急性脑梗死患者神经功能恢复的应用效果.方法 纳入2023年8月至2025年7月莆田学院附属医院收治的300例急性脑梗死患者.按随机数字表法分为两组,各150例.对照组予以常规治疗,观察组在常规治疗基础上加用依达拉奉右莰醇静脉滴注,疗程14d.采用美国国立卫生研究院卒中量表(NIHSS)和Barthel指数分别评估神经功能缺损程度及日常生活能力,检测神经元特异性烯醇化酶(NSE)、肿瘤坏死因子-α(TNF-α)及白细胞介素-6(IL-6)水平,并比较两组的功能预后及不良反应.结果 治疗后,两组NIHSS评分均随时间显著下降(P<0.001),Barthel指数均显著上升(P<0.001),且观察组在治疗后14d及90d的改善均显著优于对照组(P<0.001).治疗14d后,两组NSE、TNF-α及IL-6水平均较治疗前显著降低(P<0.001),且观察组各项指标均低于对照组(P<0.001).治疗后90d,观察组的改良Rankin量表(mRS)评分显著低于对照组[(1.88±0.43)分 vs.(2.37±0.39)分,P<0.001],预后良好率显著高于对照组(68.00%vs.54.00%,P=0.013).两组患者治疗期间不良反应发生率差异无统计学意义(P>0.05).结论 在常规治疗基础上联合依达拉奉右莰醇,可有效减轻急性脑梗死患者的炎症反应,促进神经功能恢复,显著改善患者的中期(90d)功能预后,且安全性良好.
Objective To evaluate the application effect of edaravone dexborneol on neurological function recovery in patients with acute cerebral infarction.Methods A total of 300 patients with acute cerebral infarction admitted to The Affiliated Hospital of Putian University from August 2023 to July 2025 were included.They were divided into two groups using a random number table method,with 150 patients in each group.The control group received conventional treatment,while the observation group received intravenous infusion of edaravone dexborneol in addition to conventional treatment,for a course of 14 days.The National Institutes of Health Stroke Scale(NIHSS)and the Barthel Index were used to assess neurological deficit severity and activities of daily living,respectively.The levels of neuron-specific enolase(NSE),tu-mor necrosis factor-alpha(TNF-α),and interleukin-6(IL-6)were measured.Functional outcomes and adverse reactions were compared between the two groups.Results After treatment,NIHSS scores in both groups decreased significantly over time(P<0.001),and Barthel Index scores increased significantly(P<0.001).The improvements in the observation group were significantly superior to those in the control group at 14 days and 90 days post-treatment(P<0.001).After 14 days of treatment,the levels of NSE,TNF-α,and IL-6 in both groups were significantly lower than before treatment(P<0.001),and all indicators in the observation group were lower than those in the control group(P<0.001).At 90 days post-treatment,the modified Rankin Scale(mRS)score of the observation group was significantly lower than that of the control group[(1.88±0.43)points vs(2.37±0.39)points,P<0.001],and the rate of favorable prognosis was significantly higher than that of the control group(68.00%vs.54.00%,P=0.013).There was no statistically significant difference in the incidence of adverse reactions between the two groups during treatment(P>0.05).Conclusion Combined with conven-tional therapy,edaravone dexborneol can effectively alleviate the inflammatory response in patients with acute cerebral infarction,promote neurological function recovery,significantly improve patients'medium-term(90-day)functional prognosis,and demonstrates a favorable safety profile.
朱淑云;陈超群;卢成彬
莆田学院附属医院药剂科,福建 莆田 351100莆田学院附属医院药剂科,福建 莆田 351100莆田学院附属医院药剂科,福建 莆田 351100
急性脑梗死依达拉奉右莰醇神经功能
acute cerebral infarctionedaravone dexborneolneurological function
《中华灾害救援医学》 2026 (1)
52-55,4
评论